文献速递心力衰竭与心肌病

β受体阻滞剂与Takotsubo综合征患者长期生存改善相关

Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome.
PubMed 文献 · Heart · 2022-08-11

该多中心观察性研究纳入Takotsubo意大利网络注册的825例连续患者,比较出院时使用与未使用β受体阻滞剂者的长期结局。中位随访24.0个月,校正分析显示β受体阻滞剂与全因死亡和非心源性死亡风险显著降低相关,TTS复发和心源性死亡无显著差异。

要点

  • 出院使用β受体阻滞剂与全因死亡风险降低相关(校正HR 0.563)。
  • β受体阻滞剂与TTS复发和心源性死亡无显著相关。
  • 合并高血压及急性期发生心源性休克者生存获益更明显。

核心结论

  • 在真实世界注册人群中,出院使用β受体阻滞剂与TTS患者长期生存显著改善相关。
  • 获益在合并高血压及急性期发生心源性休克的患者中更为明显。

研究设计与样本

  • 共纳入825例患者,中位年龄72.0(63.0-78.0)岁,女性占91.9%。
  • 488例(59.2%)出院时使用β受体阻滞剂,337例(40.8%)未使用;中位随访24.0个月。

主要发现

  • 校正Cox回归显示β受体阻滞剂组全因死亡风险显著更低(校正HR 0.563;95%CI 0.356至0.889)。
  • 非心源性死亡风险亦显著更低(校正HR 0.525;95%CI 0.309至0.893)。
  • TTS复发无显著差异(校正HR 0.607;95%CI 0.311至1.187),心源性死亡无显著差异(校正HR 0.699;95%CI 0.284至1.722)。
  • β受体阻滞剂的生存获益在合并高血压者中高于无高血压者(p交互=0.014),在急性期发生心源性休克者中高于未发生者(p交互=0.047)。

临床怎么用

  • 对TTS患者出院时考虑使用β受体阻滞剂以改善长期生存,尤其合并高血压或急性期发生心源性休克者。
  • β受体阻滞剂未显示降低TTS复发或心源性死亡风险,临床决策需结合个体情况。

局限性

  • 为观察性注册研究,治疗分组非随机,可能存在残余混杂。
  • 原文未报告β受体阻滞剂具体种类、剂量及依从性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The advantage of beta-blockers has been postulated in patients with Takotsubo syndrome (TTS) given the pathophysiological role of catecholamines. We hypothesised that beta-blocker treatment after discharge may improve the long-term clinical outcome in this patient population. METHODS: This was an observational, multicentre study including consecutive patients with TTS diagnosis prospectively enrolled in the Takotsubo Italian Network (TIN) register from January 2007 to December 2018. TTS was diagnosed according to the TIN, Heart Failure Association and InterTAK Diagnostic Criteria. The primary study outcome was the occurrence of all-cause death at the longest available follow-up; secondary outcomes were TTS recurrence, cardiac and non-cardiac death. RESULTS: The study population included 825 patients (median age: 72.0 (63.0-78.0) years; 91.9 % female): 488 (59.2%) were discharged on beta-blockers and 337 (40.8%) without beta-blockers. The median follow-up was 24.0 months. The adjusted Cox regression analysis showed a significantly lower risk for all-cause death (adjusted HR: 0.563; 95% CI: 0.356 to 0.889) and non-cardiac death (adjusted HR: 0.525; 95% CI: 0.309 to 0.893) in patients receiving versus those not receiving beta-blockers, but no significant differences in terms of TTS recurrence (adjusted HR: 0.607; 95% CI: 0.311 to 1.187) and cardiac death (adjusted HR: 0.699; 95% CI: 0.284 to 1.722). The positive survival effect of beta-blockers was higher in patients with hypertension than in those without (pinteraction=0.014), and in patients who developed cardiogenic shock during the acute phase than in those who did not (pinteraction=0.047). CONCLUSIONS: In this real-world register population, beta-blockers were associated with a significantly higher long-term survival, particularly in patients with hypertension and in those who developed cardiogenic shock during the acute phase.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Silverio A, Parodi G, Scudiero F, et al. Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome. Heart. 2022. PMID: 35361673. doi:10.1136/heartjnl-2021-320543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。